JSJohn E. Spiro

John E. Spiro

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


John E. Spiro has a total of 345 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Simons Sleep Project (SSP): An open science resource for accelerating scalable digital health research in autism and other psychiatric conditions

    by Micha Hacohen, Adam Levi, Hadas Kaiser, LeeAnne Snyder, Alpha Amatya, Brigitta B. Gundersen, John E. Spiro, Ilan Dinstein

    Wearable and nearable devices offer a novel opportunity to measure extensive behavioral and neurophysiological data directly from participants in their home environment. The Simons Sleep Project (SSP) was designed to accelerate research into sleep and daily behaviors in individuals with autism using such techniques. This open-science resource contains raw and processed data from Dreem3 EEG headbands, multi-sensor EmbracePlus smartwatches, and Withings Sleep mats, as well as parent questionnaires and daily sleep diaries. Data were collected successfully for >3600 days/nights from 102 adolescents (10-17 years old) with idiopathic autism and 98 of their non-autistic siblings. Whole-exome sequencing data is also available for all participants and their parents. To demonstrate the utility of this extensive dataset, we first present the breadth of synchronized high-resolution data available across multiple sensors/devices. We then demonstrate that objective sleep measures (e.g., total sleep time) from the three devices are more accurate and reliable than parent reported measures and reveal that sleep onset latency (SOL) was the only objectively defined sleep measure that differed significantly between autistic children and their siblings (of those examined in the study). Moreover, SOL was reliably associated with the severity of multiple behavioral difficulties in all children, regardless of autism diagnosis. These results highlight the importance of measuring sleep directly from participants using objective measures and demonstrate the extensive opportunities afforded by the SSP to further study autism and develop new digital phenotyping techniques for multiple research domains.

  • Open Access

    Clinical Characteristics of Seizures and Epilepsy in Individuals With Recurrent Deletions and Duplications in the 16p11.2 Region

    by Christelle Moufawad El Achkar, Alyssa Rosen, Sudha Kilaru Kessler, Kyle J. Steinman, Sarah J. Spence, Melissa Ramocki, Elysa Jill Marco, LeeAnne Green Snyder, John E. Spiro, Wendy K. Chung, et al.

    Background and Objectives Deletions and duplications at 16p11.2 (BP4 to BP5; 29.5–30.1 Mb) have been associated with several neurodevelopmental and neuropsychiatric disorders including autism spectrum disorder, intellectual disability (ID), and schizophrenia. Seizures have also been reported in individuals with these particular copy number variants, but the epilepsy phenotypes have not been well-delineated. We aimed to systematically characterize the seizure types, epilepsy syndromes, and epilepsy severity in a large cohort of individuals with these 16p11.2 deletions and duplications. Methods The cohort of ascertained participants with the recurrent 16p11.2 copy number variant was assembled through the multicenter Simons Variation in Individuals Project. Detailed data on individuals identified as having a history of seizures were obtained using a semistructured phone interview and review of medical records, EEG, and MRI studies obtained clinically or as part of the Simons Variation in Individuals Project. Results Among 129 individuals with the 16p11.2 deletion, 31 (24%) had at least one seizure, including 23 (18%) who met criteria for epilepsy; 42% of them fit the phenotype of classic or atypical Self-limited (Familial) Infantile Epilepsy (Se(F)IE). Among 106 individuals with 16p11.2 duplications, 16 (15%) had at least one seizure, including 11 (10%) who met criteria for epilepsy. The seizure types and epilepsy syndromes were heterogeneous in this group. Most of the individuals in both the deletion and duplication groups had well-controlled seizures with subsequent remission. Pharmacoresistant epilepsy was uncommon. Seizures responded favorably to phenobarbital, carbamazepine, and oxcarbazepine in the deletion group, specifically in the Se(F)IE, and to various antiseizure medications in the duplication group. Discussion These findings delineate the spectrum of seizures and epilepsies in the recurrent 16p11.2 deletions and duplications and provide potential diagnostic, therapeutic, and prognostic information.


  • Open Access

    Quantifying the Effects of 16p11.2 Copy Number Variants on Brain Structure: A Multisite Genetic-First Study

    by Sandra Martin-Brevet, Borja Rodríguez-Herreros, Jared A. Nielsen, Clara Moreau, Claudia Modenato, Anne M. Maillard, Aurélie Pain, Sonia Richetin, Aia E. Jønch, Abid Y. Qureshi, et al.


  • Top Cited Papers

    Progress in Understanding and Treating SCN2A-Mediated Disorders

    by Stephan J. Sanders, Arthur J. Campbell, Jeffrey R. Cottrell, Rikke S. Moller, Florence F. Wagner, Angie L. Auldridge, Raphael A. Bernier, William A. Catterall, Wendy K. Chung, James R. Empfield, et al.


  • Leaving the Bench and Finding Your Foundation

    by John E. Spiro

    Scientists who leave the laboratory bench to work for biomedical foundations mobilize and focus resources on the most promising research behind a foundation's mission. They acquire a broad view of a field, interact closely with research scientists at meetings and laboratory visits, and often manage proposal review boards and monitor grant progress. Increasingly, scientists at foundations also have a more active role in catalyzing research: They are involved in organizing targeted workshops, setting research priorities, and directly creating and managing resources for a scientific community. They often work closely with patient advocacy groups, contract research organizations, government funders and regulators, and biotech and pharmaceutical companies. Job opportunities in foundations are highly varied, reflecting the diversity of foundations and missions. For example, some foundations have general missions to support broad basic scientific research, whereas others focus specifically on a particular disease and may require different skills. Most scientific positions at foundations require a PhD or MD and often some postdoctoral or other experience, although not all do. Foundations often lack the clear career path that an academic position offers (various levels of professorship, tenure, etc.), although there is often significant potential for growth in responsibilities in terms of managing science, people, and budgets. Jobs in foundations can be challenging yet extremely rewarding, especially for those with broad interests and goal-oriented personalities. Many at foundations feel that they have the potential to have an even greater impact than if they had stayed at the bench.

  • Reciprocal white matter alterations due to 16p11.2 chromosomal deletions versus duplications

    by Yi Shin Chang, Julia P. Owen, Nicholas J. Pojman, Tony Thieu, Polina Bukshpun, Mari L.J. Wakahiro, Elysa J. Marco, Jeffrey I. Berman, John E. Spiro, Wendy K. Chung, et al.

    Copy number variants at the 16p11.2 chromosomal locus are associated with several neuropsychiatric disorders, including autism, schizophrenia, bipolar disorder, attention‐deficit hyperactivity disorder, and speech and language disorders. A gene dosage dependence has been suggested, with 16p11.2 deletion carriers demonstrating higher body mass index and head circumference, and 16p11.2 duplication carriers demonstrating lower body mass index and head circumference. Here, we use diffusion tensor imaging to elucidate this reciprocal relationship in white matter organization, showing widespread increases of fractional anisotropy throughout the supratentorial white matter in pediatric deletion carriers and, in contrast, extensive decreases of white matter fractional anisotropy in pediatric and adult duplication carriers. We find associations of these white matter alterations with cognitive and behavioral impairments. We further demonstrate the value of imaging metrics for characterizing the copy number variant phenotype by employing linear discriminant analysis to predict the gene dosage status of the study subjects. These results show an effect of 16p11.2 gene dosage on white matter microstructure, and further suggest that opposite changes in diffusion tensor imaging metrics can lead to similar cognitive and behavioral deficits. Given the large effect sizes found in this study, our results support the view that specific genetic variations are more strongly associated with specific brain alterations than are shared neuropsychiatric diagnoses. Hum Brain Mapp 37:2833–2848, 2016. © 2016 Wiley Periodicals, Inc.


  • Autism Spectrum Disorder, Developmental and Psychiatric Features in 16p11.2 Duplication

    by on behalf of the Simons VIP consortium, LeeAnne Green Snyder, Debra D’aNgelo, Qixuan Chen, Raphael Bernier, Robin P. Goin-Kochel, Arianne Stevens Wallace, Jennifer Gerdts, Stephen Kanne, Leandra Berry, et al.

    The 16p11.2 duplication (BP4–BP5) is associated with Autism Spectrum Disorder (ASD), although significant heterogeneity exists. Quantitative ASD, behavioral and neuropsychological measures and DSM-IV diagnoses in child and adult carriers were compared with familial non-carrier controls, and to published results from deletion carriers. The 16p11.2 duplication phenotype ranges widely from asymptomatic presentation to significant disability. The most common diagnoses were intellectual disability, motor delays and Attention Deficit Hyperactivity Disorder in children, and anxiety in adults. ASD occurred in nearly 20 % of child cases, but a majority of carriers did not show the unique social features of ASD. The 16p11.2 duplication phenotype is characterized by wider variability than the reciprocal deletion, likely reflecting contributions from additional risk factors.


  • Preprints for the life sciences

    by Jeremy M. Berg, Needhi Bhalla, Philip E. Bourne, Martin Chalfie, David G. Drubin, James S. Fraser, Carol W. Greider, Michael Hendricks, Chonnettia Jones, Robert Kiley, et al.

    The time is right for biologists to post their research findings onto preprint servers


  • Top Cited Papers
    Open Access

    Defining the Effect of the 16p11.2 Duplication on Cognition, Behavior, and Medical Comorbidities

    by Debra D’angelo, Sébastien Lebon, Qixuan Chen, Sandra Martin-Brevet, LeeAnne Green Snyder, Loyse Hippolyte, Ellen Hanson, Anne M. Maillard, W. Andrew Faucett, Aurélien Macé, et al.

    The 600-kilobase (kb) break points 4 and 5 (BP4-BP5) 16p11.2 deletion and duplications (chr16; 29.6-30.2 megabase) are among the most frequent genetic causes of autism spectrum disorder (ASD), schizophrenia, and other neurodevelopmental disorders.1-5 These reciprocal copy number variants (CNVs) are associated with mirror phenotypes of obesity and being underweight and with increased and decreased global and regional brain volumes in deletion and duplication carriers, respectively.6-8 Previous studies5,9 have demonstrated that ASD is diagnosed in approximately 18% of deletion carriers and that this CNV affects global cognition by shifting the IQ approximately 2 SDs without altering the variance. To our knowledge, such studies have not been conducted for the reciprocal duplication. Akin to duplications of other genomic regions, case series10-18 have reported variable expressivity and suggested incomplete penetrance; however, incomplete penetrance was recently ruled out after recalling carriers identified in unselected populations.19 This phenotypic variability and the limited available data underscore the need to systematically characterize the clinical impact of the duplication with standardized assessments in large numbers of carriers.


  • Clinical phenotype of the recurrent 1q21.1 copy-number variant

    by Raphael Bernier, Kyle J. Steinman, Beau Reilly, Arianne Stevens Wallace, Elliott H. Sherr, Nicholas Pojman, Heather C. Mefford, Jennifer Gerdts, Rachel Earl, Ellen Hanson, et al.